NUTEX HEALTH ANNOUNCES NASDAQ DELISTING NOTIFICATION AND STAY PENDING ONGOING APPEAL. NO IMMEDIATE EFFECT ON THE LISTING OR TRADING OF THE COMMON STOCK.

Core Viewpoint - Nutex Health Inc. is facing potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement, but has requested a hearing to appeal this decision [1][2]. Group 1: Delisting and Compliance - On May 21, 2024, Nasdaq notified Nutex Health that its common stock would be delisted due to not meeting the minimum bid price of $1.00, with trading suspension set for May 30, 2024, unless a hearing is requested [1]. - The company submitted a request for a hearing on May 23, 2024, which has temporarily stayed the delisting action, with a hearing scheduled for July 9, 2024 [2]. - The company plans to submit a written response by May 30, 2024, which may allow the Panel to decide without an oral hearing [2]. Group 2: Reverse Stock Split - The Board of Directors approved a reverse stock split with a ratio between 1-for-2 and 1-for-16, pending shareholder approval on June 17, 2024, to regain compliance with Nasdaq's requirements [3]. - The company acknowledges the uncertainty of regaining compliance and obtaining a favorable decision from the Panel [3]. Group 3: Company Overview - Nutex Health Inc. is a healthcare management company founded in 2011, operating 21 micro hospitals across nine states and focusing on integrated healthcare delivery [5]. - The company has two divisions: a Hospital Division that operates innovative healthcare models and a Population Health Management Division that manages provider networks and offers administrative support services [6].